Two studies recently reported in The Lancet have identified risk factors for mortality among patients with cancer and COVID-19.1,2 As reported by Lennard Y.W. Lee, DPhil, of the Institute of Cancer and Genomic Sciences, University of Birmingham, and colleagues,1 a UK prospective cohort study performed by the UK…
The FDA approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)—includi…
On April 23, the FDA granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age and older with…
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on…
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment…
In the single-center phase II Natalie trial reported in The Lancet Oncology, investigators assessed the activity of cabozantinib in patients with unresectable and progressive metastatic…
On April 22, the U.S. Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva) with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle invasive…
Investigators have examined whether following certain healthy diets may reduce the risk of cardiovascular disease in female breast cancer survivors.
Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer.
In the single-center phase II Natalie trial reported in The Lancet Oncology, investigators assessed the activity of cabozantinib in patients with unresectable and progressive metastatic…
The phase I/II CheckMate 358 trial assessed nivolumab monotherapy and nivolumab/ipilimumab regimens in patients with recurrent or metastatic cervical squamous cell carcinoma. The study findings…
